A study of Mipsagargin in combination with Sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma (HCC), or liver cancer

Trial Profile

A study of Mipsagargin in combination with Sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma (HCC), or liver cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Mipsagargin (Primary) ; Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 New trial record
    • 30 May 2017 According to an Inspyr Therapeutics media release, the company is finalising the trial design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top